Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis

The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Sci Rep
Main Authors: Im, Seock-Ah, Xu, Binghe, Li, Wei, Robson, Mark, Ouyang, Quchang, Yeh, Dah-Cherng, Iwata, Hiroji, Park, Yeon Hee, Sohn, Joo Hyuk, Tseng, Ling-Ming, Goessl, Carsten, Wu, Wenting, Masuda, Norikazu
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7260217/
https://ncbi.nlm.nih.gov/pubmed/32472001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-63033-4
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker